Posted by Michael Wonder on 22 Apr 2024
UCB receives European Commission approval for Bimzelx (bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa
22 April 2024 - Approval is supported by data from two Phase 3 studies, BE HEARD I and BE HEARD II, in which bimekizumab significantly improved the signs of disease compared with placebo at week 16, which were sustained to Week 48, and was well-tolerated.
UCB, a global biopharmaceutical company, today announced that the European Commission has granted marketing authorisation for Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa in adults with an inadequate response to conventional systemic HS therapy.
